| Market Capitalization (Millions $) |
5,736 |
| Shares
Outstanding (Millions) |
434 |
| Employees |
170 |
| Revenues (TTM) (Millions $) |
5 |
| Net Income (TTM) (Millions $) |
-176 |
| Cash Flow (TTM) (Millions $) |
126 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Dbv Technologies S.A. is a biopharmaceutical company that specializes in developing immunotherapy treatments for various allergic diseases. The company is based in France and was founded in 2002.
Dbv Technologies is known for its innovative approach to treating allergies, particularly through its Viaskin® platform. This platform utilizes epicutaneous immunotherapy (EPIT) to deliver allergens to patients through a patch worn on the skin. By gradually exposing the immune system to small doses of allergens, the company aims to desensitize patients and reduce allergic responses.
The company's lead product, Viaskin Peanut, is currently under development for the treatment of peanut allergies, which is a common and potentially life-threatening allergy. Dbv Technologies has conducted clinical trials to assess the efficacy and safety of Viaskin Peanut, and the results have been promising. If approved, Viaskin Peanut could become a significant breakthrough in the treatment of peanut allergies.
Dbv Technologies is also investigating potential applications of its Viaskin platform for other allergens, including milk, eggs, and other food allergies. The company has ongoing research and development efforts to expand its product portfolio and address unmet medical needs in the field of allergies.
In summary, Dbv Technologies S.A. is a biopharmaceutical company focused on developing immunotherapy treatments for allergies. Through its Viaskin platform, the company aims to revolutionize the treatment options for patients suffering from allergic diseases, potentially improving their quality of life.
Company Address: 107 Av. de la République Châtillon 92320
Company Phone Number: 1 55 42 78 78 Stock Exchange / Ticker: NASDAQ DBVT
|
